The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Aberdeen And Lloyds Jump On Scottish Widows Investment Partnership Deal

Mon, 18th Nov 2013 12:13

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Monday.

-------

FTSE 100 - Winners

Aberdeen Asset Management is up 13%. The company is set to become the world's largest listed fund manager after it agreed a deal to buy Scottish Widows Investment Partnership Group Ltd. from Lloyds Banking Group for up to GBP660 million. Aberdeen, which had GBP200.4 billion in assets under management at the end of September, will add about GBP136 billion more by buying the business with annual revenues of about GBP234 million. Separately, Aberdeen raised its total dividend for its last financial year after reporting higher earnings, assets under management and revenue. The asset manager said revenues rose to GBP1.08 billion in the year to end-September, from GBP869.2 million a year earlier, while pretax profit rose to GBP390.3 million, from GBP269.7 million. It raised its total dividend to 16.0 pence, from 11.5p, as assets under management totalled GBP200.4 billion at the end of the year, up from GBP187.2 billion a year earlier.

Lloyds Banking Group, up 1.1%, is also benefiting on the back of the deal to sell Scottish Widows Investment Partnership. Lloyds said it expects to book an after-tax gain of GBP190 million on the disposal.

Rolls-Royce Holdings climbs 0.8% after it won a USD5 billion order from Etihad Airways to provide engines and long-term support for 50 Airbus A350 XWB aircraft.

-------

FTSE 100 - Losers

Petrofac, down 17%, is the biggest faller on the FTSE 100, despite saying that it is on track to deliver modest net profit growth for its full year. "Project slippages have reduced 2014 expectations and increased the risk that the 2015 earnings target will be missed," Liberum Capital says. Toby Morris, senior sales trader at CMC Markets, echoes this sentiment, saying that the statement "all but extinguished strong 2014 growth targets, with the deferral of a major project pointing towards a flat year or modest growth forecast at best."

Capita is down 1.3%. Although the company said that it is on track to post strong growth in the current financial year, the company's share price has fallen after it reported that Chief Executive Paul Pindar will leave at the end of February to pursue private equity opportunities and that it sold a package of financial products businesses at a loss.

-------

FTSE 250 - Winners

Kentz Corporation is up 1.5% after it reiterated guidance that it will deliver double-digit earnings growth in 2013 on the back of new contracts and strong order intake. The company said it saw a strong order intake of USD1.8 billion in the first ten months of 2013, as it was awarded new contracts in the Middle East, Russia and the Americas. Kentz anticipates a number of awards before year end, and its operations continue to trade in line with expectations, with in excess of 60% of orders for 2014 already under contract.

-------

FTSE 250 - Losers

Aveva Group is off 8.4%. The software company said its operating expenses increased 12% to GBP73.0 million from GBP65.0 million and there was slower-than-expected growth in its enterprise solutions division, which will lead to lower-than-expected revenue for that division for the full financial year. Panmure Gordan has increased Aveva's price target to 2,386.00p from 2,374.00p.

-------

AIM - Winners

Mediwatch jumps 38% after Laborie Medical Technologies Europe said it had made a recommended GBP8.48 million offer for the company, and already has irrevocable undertakings from Mediwatch shareholders with about 33% of its share capital. The offer price represents a 118% premium to Mediwatch's closing price October 17.

Armadale Capital climbs 23%. The investment company said its 40% owned Mining Restoration Investments has successfully commenced commercial coal briquetting operations in South Africa. Armadale also said it remains focused on increasing its investment in Netcom Global Inc, which holds a right to an interest in the highly prospective Mpokoto Gold Project in the Democratic Republic of Congo.

Synety Group is up 11% after it said it has been granted a US telecoms licence, meaning it can now start offering its CloudCall telecoms service to businesses and residents in the country.

Redcentric is up 10%. The company will buy the managed service unit of InTechnology for GBP65 million in cash and launched a GBP64 million placing to help pay for the deal. In a statement, Redcentric said the deal will be transformational, doubling total revenues and increasing its recurring revenues to more than 80%.

Ultrasis is up 8.1% after its recently-acquired screening and well-being subsidiary, Screenetics UK won three new contracts with customers in the public and private sectors worth an estimated GBP2 million a year. The contracts are for the provision of flu vaccinations, health screenings for staff at a public sector body and employee screening for a large UK corporate.

-------

AIM - Losers

Akers Biosciences is off 17% after it announced the conversion of preferred shares and consolidation of its issued share capital ahead of the company's proposed listing on Nasdaq in the US. The biotechnology company said 10 million preferred shares, which are held by Director Thomas Knox, are to be converted into 50 million new common shares with the payment of USD500,000 to the company. Under the share consolidation plan, shareholders will exchange 156 existing shares for 1 new consolidated common share. Following the conversion and consolidation, the company will have 2.1 million shares in issue.

Provexis slips 15%, having jumped 77% since the beginning of November. The company has said that it knows of no reason why its share price has increased during the month.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
23 Jan 2014 18:16

Akers Bioscience To Recommence Trading On AIM, Prices Offering

LONDON (Alliance News) - Akers Biosciences Inc said Thursday that its shares will recommence trading on AIM Friday, and announced the pricing of its public offering on the NASDAQ. Akers Biosciences will offer 2.7 million shares at USD5.50 each, hoping to raise around USD15 million in gross

Read more
18 Nov 2013 11:02

Akers Biosciences To Convert Preferred Shares, Consolidate Shares Ahead Of NASDAQ Listing

Read more
15 Nov 2013 14:55

Akers Narrows Nine Month Pretax Losses As Revenues Rise

Read more
19 Jul 2013 07:28

Akers Biosciences revenue ahead of expectations

Akers Biosciences said first-half revenue was ahead of its own expectations after it capitalised on demand for its disposable breath alcohol detectors. In a trading update, Akers said it had delivered 4.9m of the detectors to its global partner, Chubeworkx. The Chube-branded detectors are certifi

Read more
10 Apr 2013 12:30

STOCKS NEWS EUROPE-UK small caps up 0.1 pct, lag blue chips

UK small caps are up 0.1 percent in afternoon trade, underperforming rises of 0.8 percent on both the mid-caps and the blue chips. Shares in Akers Biosciences jump 22 percent to 1.45 pence after the maker of rapid diagnostic screening and testing products says it expects full-year sales to

Read more
19 Feb 2013 12:02

STOCKS NEWS EUROPE-UK small caps up 0.1 percent at midday

The FTSE Small Cap index is 0.1 percent higher in midday trade, trailing blue chips, up 0.4 percent, and midcaps, which rise 0.7 percent. Akers Biosciences, a designer and manufacturer of rapid diagnostic screening and testing products, jumps 11 percent as it says sales of its test for hepa

Read more
19 Feb 2013 11:27

Akers Biosciences gets boost from new French regulation

Akers Biosciences was rewarded with a 11.3 per cent jump in its share price as the company announced a new product launch into the French market. The launch of disposable breath alcohol analysis tools is timely, as it coincides with a new French law coming into effect as of July 2012 citing that e

Read more
17 Sep 2012 07:34

Small caps: Iofina, WYG, Akers Biosciences

WYG, a management and technical consultancy to the built and natural environment, says it will report a small operating profit in the first six months of the current year. The group is also poised to buy all three of WYG Ireland's subsidiaries in Northern Ireland, securing the jobs of around 90 empl

Read more
6 Jan 2012 17:17

London close: Footsie finishes below best levels

London closed comfortably below its best levels of the day despite better than expected US jobless data which had some market commentators crying 'foul'. US non-farm payrolls grew by 200,000 during the month of December. The consensus estimate was for a reading of 155,000. Morgan Stanley has sugges

Read more
6 Jan 2012 09:31

Akers' profit expectations down the tubes

Diagnostic screening and testing products developer Akers Biosciences slumped to a 52-week low after warning that 2011 revenues will not come up to scratch. Largely as a result of issues with an order for Revelar Breath Tubes from Pulse Health, revenues for 2011 will be significantly below expectat

Read more
11 Apr 2011 16:00

Akers narrows losses after sales surge in 2010

Shares in screening and testing products group Akers Biosciences surged after the company reported a 72% increase in revenue after a "momentum-building" year. Revenue for the 12 months ended 31 December grew to $3.1m, from $1.8m in 2009, as a result of strong sales of its HIT-testing product ('PIFA

Read more
14 Jan 2011 14:00

Small caps round-up: Superglass, Akers Biosciences, TT electronics...

Insulation products maker Superglass is experiencing solid trading with specialist distributors and builders' merchants, but, as anticipated, there has been a slow start to the newly extended carbon emissions reduction target (CERT) programme. The expectation is that the company's trading performa

Read more
21 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Eckoh Sees Return To 1H 2011 Profit

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps ECKOH PLC (ECK.LN), a voice recognition specialist, expects to return to a profit in the first half of fiscal 2011 after posting a narrowed pretax loss f

Read more
21 Jun 2010 12:30

UK SMALLCAP ROUNDUP: Photo-Me Fined GBP500,000 By FSA

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps PHOTO-ME INTERNATIONAL PLC (PHTM.LN), a photo booth operator, was Monday fined GBP500,000 by the U.K. Financial Services Authority for failing to keep in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.